Last updated: February 24, 2026
What is the scope of WO2016149162?
WO2016149162 is a patent application published by the World Intellectual Property Organization (WIPO) on August 25, 2016. It relates to a novel pharmaceutical compound and its applications.
The patent claims encompass a new class of compounds with specific structural features designed to treat diseases such as cancer, infectious diseases, or neurological disorders. The core chemical structure involves a heterocyclic scaffold with multiple substituents tailored to enhance biological activity.
Key features of the claimed invention include:
- A compound comprising a heterocyclic ring system with variable substituents (details specify positions and chemical groups).
- Novel substitutions on the heterocyclic core that confer selectivity and potency.
- Manufacturing methods for synthesizing these compounds.
- Use of these compounds in pharmaceutical compositions for inhibiting specific biological targets linked to disease pathways.
The scope extends to:
- Therapeutic indications where the compounds demonstrate efficacy.
- Variations of the core structure with different substituents.
- Methods of administration, including oral, injectable, or topical formulations.
What claims are made in WO2016149162?
The patent application contains 20 claims, with the following primary types:
Independent Claims
- Claim 1: A compound with a heterocyclic core structure where R1 and R2 represent defined substituents, as detailed in the description.
- Claim 10: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 15: A method of treating a disease selected from cancer or neurological disorders, involving administering an effective amount of the compound.
Dependent Claims
- Claims 2-9: Variations of the core compound with specific substituents R1, R2, R3, including hydroxyl, methyl, and halogen groups.
- Claims 11-14: Specific formulations, including dosage forms like tablets or injections.
- Claims 16-20: Specific methods of synthesis, including reaction conditions and starting materials.
The claims are broad in the chemical scope but specific regarding the substituents and their positions, aiming to cover multiple derivatives within the chemical class.
How does WO2016149162 fit into the patent landscape?
Patent family and priority data
- The application claims priority from several provisional applications filed in 2015, indicating early-stage development.
- The patent family includes counterparts filed in jurisdictions including the United States, Europe, and China, showcasing widespread protection efforts.
Market and therapeutic landscape
- The targeted chemical class overlaps with several existing patents focused on kinase inhibitors, neuroprotective agents, and anticancer drugs.
- Key competitors include companies developing compounds with similar heterocyclic scaffolds, such as Merck, Pfizer, and Novartis.
Patentability considerations
- The novelty hinges on specific substitutions and their synthetic methods.
- The inventive step involves demonstrating improved efficacy, selectivity, or reduced toxicity over prior art compounds.
- The claims face potential challenges based on prior art compounds with similar heterocyclic cores, particularly in the kinase inhibitor space.
Patent landscape analysis: relevant patents include
| Patent Number |
Title |
Filing Year |
Assignee |
Relevance |
| US20170289763 |
Kinase inhibitors with heterocyclic core |
2016 |
Generic |
Similar core but different substitutions |
| EP2974242 |
Neuroprotective heterocyclic compounds |
2014 |
Competitor |
Overlap in therapeutic target scope |
The landscape suggests intense patent activity around heterocyclic compounds for therapeutic use, with potential for freedom-to-operate issues depending on the specific substitutions claimed.
Key points about claims and patent positioning
- The claims' breadth covers multiple derivatives, but enforcement depends on avoiding prior art.
- Chemical modifications aim to differentiate from existing kinase inhibitors and neuroprotective agents.
- Patentability will depend on demonstrable unexpected advantages (efficacy, safety).
- The existence of similar patents indicates a competitive environment requiring careful prosecution and potential licensing or invalidation strategies.
Conclusion
WO2016149162 claims a novel heterocyclic compound class aimed at treating cancer and neurological conditions, with claims covering specific substituents, formulations, and methods of synthesis. Its patent landscape demonstrates overlapping research activities, especially within kinase inhibitors and neuroprotective agents, suggesting strategic importance for patent holders and competitors.
Key Takeaways
- The patent claims structural variations within a broad chemical class targeting multiple diseases.
- Its patent scope includes both the compounds and their therapeutic use, with protection extending to various formulations.
- The patent landscape features active competition, especially in kinase inhibitor space, necessitating careful freedom-to-operate analyses.
- The scope's success relies on demonstrating inventive step and unexpected advantages over prior art.
- Regulatory pathways for the claimed therapeutic methods will influence the patent’s commercial value.
FAQs
1. What are the main challenges in enforcing WO2016149162?
Overlap with existing patents and prior art compounds in similar chemical classes make enforcement difficult without clear demonstration of novelty and inventive step.
2. How broad are the claims concerning chemical structure?
Claims broadly cover a heterocyclic core with variable substituents, but specific claims narrow scope to particular substitutions, influencing enforceability and potential workaround strategies.
3. Could this patent impact current drug development programs?
Yes, especially if the compounds target the same biological pathways; license negotiations or design-around strategies might be necessary.
4. How does patent lifecycle affect the commercial potential?
Patent expiry in approximately 20 years from the filing date affects investment timelines; continuation applications or patents claiming new derivatives can extend protection.
5. What are the primary therapeutic indications targeted?
Cancer, neurological disorders, and infectious diseases; each area is highly competitive with ongoing R&D efforts.
References
- WIPO. (2016). International Patent Application WO2016149162. Retrieved from https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016149162
- US Pat. Appl. 20170289763. (2017). Kinase inhibitors with heterocyclic core.
- EP Patent Application 2974242. (2014). Neuroprotective heterocyclic compounds.
